Consequently, the inhibition of TGFβ or the deactivation of the TGFβ receptor on NK or CAR-NK cells has the potential to counteract TGFβ-mediated inhibition and enhance NK anti-cancer activity [187,188,189,190,191,192]. This evidence concerns the gene TGFB1 and cancer.